Chris Howerton
Stock Analyst
(3.08)
# 4,648
Out of 4,648 analysts
74
Total ratings
42.37%
Success rate
12.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $39.74 | +98.79% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.48 | +170.27% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.73 | +36.30% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $20 → $22 | $0.64 | +3,311.38% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $13.54 | +5,217.58% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.64 | -69.51% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $11.93 | -16.18% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $3.06 | -34.64% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $14.86 | -25.98% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $28.56 | +40.06% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $33.05 | +84.57% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $87.25 | +3.15% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $5 | $5.89 | -15.11% | 4 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.85 | +147.42% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $15.69 | +703.06% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.18 | +1,594.92% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $25.39 | +159.94% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.04 | +2,784.62% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.19 | +323.89% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $5.08 | +313.39% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $2.26 | +873.45% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.77 | +1,199.44% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $14.62 | +43.64% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.81 | +3,491.78% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.55 | +3,770.97% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $50.06 | -68.04% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $46.76 | -42.26% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.26 | +9,028.95% | 1 | May 26, 2020 |
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $39.74
Upside: +98.79%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.48
Upside: +170.27%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.73
Upside: +36.30%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $20 → $22
Current: $0.64
Upside: +3,311.38%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $13.54
Upside: +5,217.58%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.64
Upside: -69.51%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $11.93
Upside: -16.18%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $3.06
Upside: -34.64%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $14.86
Upside: -25.98%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $28.56
Upside: +40.06%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $33.05
Upside: +84.57%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $87.25
Upside: +3.15%
Mar 2, 2022
Upgrades: Buy
Price Target: $1 → $5
Current: $5.89
Upside: -15.11%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.85
Upside: +147.42%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $15.69
Upside: +703.06%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.18
Upside: +1,594.92%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $25.39
Upside: +159.94%
Aug 24, 2021
Initiates: Buy
Price Target: $30
Current: $1.04
Upside: +2,784.62%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.19
Upside: +323.89%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $5.08
Upside: +313.39%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $2.26
Upside: +873.45%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.77
Upside: +1,199.44%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $14.62
Upside: +43.64%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.81
Upside: +3,491.78%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.55
Upside: +3,770.97%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $50.06
Upside: -68.04%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $46.76
Upside: -42.26%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.26
Upside: +9,028.95%